1. World Health Organization (WHO).Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms;Technical Report Series, No 937, 40th Report, Annex 8 of WHO Expert Committee on Specifications for Pharmaceutical Preparations,2006
2. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER);Guidances for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System,2000
3. European Medicines Agency (EMA), Committee for Medicinal Products of Human Use (CHMP);Guidance on the Investigation of Bioequivalence,2010
4. International Pharmaceutical Federation (FIP);Biopharmaceutics Classification System (BCS),2009
5. World Health Organization (WHO);Guidance on INN,1997